CMRO Stock UPDATES Comarco Inc. (CMRO) 0.1510 08/03/2014 06:

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Comarco Inc. (CMRO) 0.1510 $CMRO

Great East Energy Generating Revenues for Investors with Clean Energy Assets in Lucrative European Market
Marketwire - Thu Feb 13, 7:30AM CST
Great East Energy, Inc. (OTCQB: GASE) saw an opportunity to build an energy footprint in Europe's second largest country with regard to land mass, and completed a deal late in 2013 that has it controlling more than 160 square miles of producing clean energy assets in Ukraine. With it, the company immediately controlled more than just a large piece of property -- Great East Energy could now generate revenue in a lucrative energy market for its investors.

MobileHealth App Patient Buddy Winner of ACT-IAC Incubator Award
PR Newswire - Wed Feb 12, 3:00PM CST
Creative Information Technology, Inc. (CITI), a growing mid-tier IT firm, based in Northern Virginia announced today that its latest innovation for the mobile health market, Patient Buddy(TM), was honored at the ACT-IAC's (American Council for Technology and Industry Advisory Council) first-ever Igniting Innovation technology competition, held on Thursday, February 6, at the Ronald Reagan Building and International Trade Center, in Washington, DC. Patient Buddy, a first-of-its-kind health care IT solution, was selected as one of the top eight finalists (out of 30 finalists, which were picked out of the original 86 entries), and ultimately was selected by a panel of 4 judges to win the ACT-IAC Incubator Award.

Jury Awards Comarco Net $9.7 Million Verdict
PR Newswire - Wed Feb 05, 8:30AM CST
Comarco, Inc. (OTC:CMRO.PK) ("the Company" announced that on February 4, 2014, the jury returned a verdict in favor of the Company in its previously reported litigation with Chicony Power Technology, Co. Ltd ("Chicony" and awarded the Company damages of approximately $10.8 million, offset by previously accrued liabilities of $1.1 million for a net award to Comarco of approximately $9.7 million.

Covisint Names Three New, Independent Members to Its Board of Directors
GlobeNewswire - Thu Jan 16, 3:57PM CST
-- Dave Hansen, President and CEO of Data Protection Company SafeNet

Faruqi & Faruqi, LLP Launches an Investigation against Comarco, Inc. (CMRO) for Potential Breaches of Fiduciary Duties by Its Board of Directors
Business Wire - Fri Jul 12, 6:00PM CDT
Juan E. Monteverde, a partner at Faruqi & Faruqi, LLP, a leading national securities firm headquartered in New York City, is investigating the Board of Directors of Comarco, Inc. ("Comarco" or the "Company" (OTC Markets: CMRO) for potential breaches of fiduciary duties in connection with their conduct in seeking shareholders' approval for an amendment to the Company's 2011 Equity Incentive Plan.

Comarco Q1 revenue down 36%
M2 - Mon Jun 17, 12:50PM CDT
Comarco, Inc. (OTC: CMRO) said that for the first fiscal quarter ended April 30, 2013, revenue for the first quarter of fiscal 2014 was USD1.4m, a decrease of 36% compared with USD2.2m in revenue for the first quarter of fiscal 2013.

Comarco's net loss widens in Q1 fiscal 2014
M2 - Mon Jun 17, 3:22AM CDT
Comarco Inc (OTC:CMRO.PK) on Friday reported a net loss of USD1.5m, or USD0.11 per share, for the first quarter of fiscal 2014, ended 30 April 2013.

Comarco Reports First Quarter Fiscal 2014 Financial Results
PR Newswire - Fri Jun 14, 4:00PM CDT
Comarco, Inc. (OTC: CMRO.PK) today announced its financial results for the first fiscal quarter ended April 30, 2013. The Company also filed its Quarterly Report on Form 10-Q for the first quarter of fiscal year 2014 with the Securities and Exchange Commission today.

Comarco Reports Fiscal 2013 Fourth Quarter and Full Year Financial Results
PR Newswire - Tue Apr 30, 4:00PM CDT
Comarco, Inc. (OTC: CMRO.PK), today announced its financial results for the fourth fiscal quarter and full fiscal year ended January 31, 2013. The Company also filed its Annual Report on Form 10-K for fiscal year 2013 with the Securities and Exchange Commission today.

Comarco closes $1.5 million debt and equity transaction from institutional investor
M2 - Wed Feb 13, 5:31AM CST
Comarco, Inc. (OTC: CMRO) reported it has consummated a $2.5 million debt and equity financing transaction with Elkhorn Partners Ltd. Partnership, an existing shareholder of the company.

Comarco suffers revenue loss
M2 - Mon Dec 17, 1:26PM CST
Comarco, Inc. (OTC: CMRO) said its revenue for the third quarter of fiscal 2013 was $1.1 million compared to $2.3 million for the third quarter of fiscal 2012.

Comarco widens loss in Q3 fiscal 2013
M2 - Mon Dec 17, 4:39AM CST
Comarco Inc (OTC: CMRO.PK) on Friday reported a net loss of USD2.2m, or USD0.29 per share, for the third quarter of fiscal 2013, ended 31 October 2012.



Scroll down for more posts ▼

Top 10 Most Recent News Articles

Ivonescimab Promises New Hope for Advanced BTC Patients

Updated Category News Views 280

Shifting the Paradigm in Biliary Tract Cancer Treatment Here's the scoop from the bustling world of oncology: the trial of Ivonescimab plus chemotherapy is stirring waves among experts in advanced biliary tract cancer (BTC). Contrary to the usual drowsy mornings with coffee and market pages, this data from Hong Kong wasn't about Wall Street this time. This trial might...

Continue Reading
LexisNexis Debuts AI-Guided Field Clarity at IACP 2026

Updated Category News Views 84

LexisNexis Takes a Serious Step Forward The world of law enforcement reporting just got a shake-up. LexisNexis Coplogic Solutions launched a souped-up version of its Desk Officer Reporting System (DORS) at the IACP 2026 event. They paired DORS with Field Clarity, a newfangled AI-powered assistant that aims to make police reporting slicker and more accurate. You can bet...

Continue Reading
Wenda Pharma's NHWD-870 HCl Shows Promise in Trial

Updated Category News Views 393

Breaking Through in NUT Carcinoma Treatment Imagine battling an aggressive disease with barely any options left, and then something hopeful shows up in the pipeline. That's the story with Zhejiang Wenda Pharma's NHWD-870 HCl, an oral BET inhibitor making waves at the 2026 ESMO Annual Meeting. Facing off against the nasty beast that is NUT carcinoma, this drug didn't just...

Continue Reading
Lilly's Olomorasib: New Data Sparks Hope for G12C NSCLC

Updated Category News Views 186

New Data Unveiling Potential Shifts in NSCLC Treatment Man, if there's one thing the oncology world craved, it's progress against KRAS G12C-mutant non-small cell lung cancer (NSCLC). We're talking about a challenge as tough as a two-dollar steak. But hey, Eli Lilly's (NYSE:LLY) putting some serious cards on the table with olomorasib, and folks at the ESMO 2026 Congress...

Continue Reading
Clarins Dazzles Austin with Skin Longevity Event

Updated Category News Views 21

Clarins Takes Austin by Storm Under the vast Austin sky, something remarkable unfolded as Clarins transformed the scene with a flashy rooftop affair that screamed innovation and elegance. They weren’t just showing off fancy bottles of beauty potion; they were stirring the pot, merging science with a splash of high-end glitz. This wasn’t just another product pitch—it...

Continue Reading
Innovent's IBI3001 Shows Promise in Phase 1 Trials

Updated Category News Views 299

Pioneering Path with IBI3001 at ESMO 2026 Navigating through the crowded landscape of oncology trials, Innovent Biologics recently rolled out some riveting Phase 1 clinical data for their new darling, IBI3001. Top brass from Innovent took to the European Society for Medical Oncology (ESMO) Congress stage to lay bare their findings. Obviously, when you're presenting a...

Continue Reading
Sinclair Faces Labor Lawsuit for Break-time Violations

Updated Category News Views 175

Sinclair Television Caught in Labor Law Storm When you think of flaring tempers and boardroom brawls, you typically don't think of your everyday TV station. But right now, Sinclair Television of California, LLC is in the hot seat, accused of playing fast and loose with wage packets—specifically, allegedly denying meal periods and rest breaks that California labor laws...

Continue Reading
Johnson & Johnson's JNJ-6143 Shines in Prostate Cancer Study

Updated Category News Views 241

Prostate Cancer's Persistent Challenge No one in the healthcare game needs the reminder: prostate cancer is no walk in the park, especially for those grappling with advanced stages. Now picture this—you're on your sixth treatment, and the cloud is not lifting. It's a battle that never ends, with traditional therapies sometimes barely holding the line. JNJ-6143's New...

Continue Reading
Gildan Activewear Faces Legal Battle Over Alleged Fraud

Updated Category News Views 176

Investor Alert: Gildan's Legal Showdown Alright, here's a twist you didn't see coming—or maybe you did if you've been tracking the ticker tapes like a hawk. Gildan Activewear Inc. (NYSE:GIL) is stuck in the kind of hot water that can scald the bottom line. The Stakes: Racing Towards December 14 Marked on your calendar, December 14, is a date of some significance if...

Continue Reading
DigitalXForce Shakes Up GRC: AI-Infused X-ROC Launch

Updated Category News Views 98

Turning Risk Management on Its Head Well, here's a company not just tinkering around the edges but flipping the script on Governance, Risk, and Compliance (GRC) with their latest rollout: DigitalXForce and its X-ROC. Yeah, it's yet another acronym to juggle, but don't roll your eyes just yet. This AI-driven beast isn't about occasional boardroom reports. No sir, it's a...

Continue Reading

Top 5 Most Recently Viewed Articles

Exploring Schouw & Co.'s Share Buy-Back Strategy for 2025

Updated Category News Views 153

Overview of Schouw & Co.'s Share Buy-Back Program Schouw & Co. has launched an exciting share buy-back initiative, aiming to enhance shareholder value significantly. This program began on May 5, 2025, and is designed to repurchase shares totaling up to DKK 120 million. This investment runs until December 31, 2025, reflecting the company's commitment to its shareholders....

Continue Reading
Schneider National Plans to Reveal Q3 2024 Earnings Soon

Updated Category News Views 45

Schneider National to Report Third Quarter 2024 Earnings Schneider National, Inc. (NYSE: SNDR), a leader in transportation and logistics services, has announced that it will release its third quarter 2024 earnings report on a future date, ahead of the market opening. This announcement is significant as it highlights the company’s continued focus on financial...

Continue Reading
A Closer Look at BioAge Labs: Legal Challenges Ahead

Updated Category News Views 206

Understanding the Legal Landscape of BioAge Labs Investors in BioAge Labs, Inc. have faced new uncertainties as the clinical-stage biopharmaceutical company becomes entangled in legal challenges. As the firm moves forward in its mission to develop innovative therapies aimed at combating metabolic diseases, significant developments have emerged that every investor should...

Continue Reading
Celebrating the Fusion of Science and Cinema at Starmus 2025

Updated Category News Views 202

Fusion of Science and Cinema at Starmus Festival The Starmus Festival is a unique event that intertwines science and art, culminating in extraordinary dialogues and presentations. Recently, renowned director Christopher Nolan was awarded the prestigious Stephen Hawking Medal for Science Communication during this remarkable celebration. This accolade is not just an honor...

Continue Reading
Millicom Takes Steps to Enhance Transparency in Holdings

Updated Category News Views 82

Millicom Takes Steps to Enhance Transparency in Holdings Millicom International Cellular S.A., commonly recognized as Tigo, is making significant strides in open communication and compliance by submitting regulatory notifications regarding major shareholder holdings. This initiative reinforces their commitment to transparency and regulatory excellence in the ever-evolving...

Continue Reading